(Source: Business Wire)
Accelr8 Technology Corporation (NYSE Amex: AXK) announced today
that it has concluded a technical development project with Becton,
Dickinson and Company ("BD") (NYSE: BDX). Accelr8's technology met
formal testing requirements for identification of a subset of relevant
species of bacteria. However, BD advised the Company that it has decided
to decline an associated exclusive technology license option. At any
time, BD has numerous new product opportunities, and prioritizes
projects on the basis of decision criteria that are not limited to
technical factors.
According to David Howson, Accelr8's president, "We're disappointed by
BD's decision not to exercise its exclusive option. Nevertheless, we
made substantial advances and gained strong supporting technical
evidence in the project, including integrated testing using patient
specimens. We will continue discussions with other prospective
collaborators. The BACcel rapid diagnostic system remains the only
technology yet supported by published data to have the capability to
provide same-day analysis of all significant highly drug-resistant
bacteria and their particular resistance mechanisms."
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com)
is a developer of innovative materials and instrumentation for advanced
applications in medical instrumentation and biosciences basic research.
Accelr8 is developing a rapid clinical pathogen diagnostic platform, the
BACcel, based on its wholly-owned intellectual property. In addition,
Accelr8 licenses certain of its proprietary technology for use in
applications outside of Accelr8's own products.
Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Statements regarding future prospects and developments
are based upon current expectations and involve certain risks and
uncertainties that could cause actual results and developments to differ
materially from the forward-looking statement, including those detailed
in the company's filings with the Securities and Exchange Commission.
Accelr8 does not undertake an obligation to publicly update or revise
any forward-looking statements, whether as a result of new information
or future events.
A service of YellowBrix, Inc.
